AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
94,300
Employees94,300
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
94,300
Employees94,300

AZN Key Statistics

Market cap
264.17B
Market cap264.17B
Price-Earnings ratio
31.23
Price-Earnings ratio31.23
Dividend yield
1.83%
Dividend yield1.83%
Average volume
6.52M
Average volume6.52M
High today
$85.06
High today$85.06
Low today
$83.13
Low today$83.13
Open price
$83.85
Open price$83.85
Volume
3.13M
Volume3.13M
52 Week high
$86.57
52 Week high$86.57
52 Week low
$61.24
52 Week low$61.24

AZN News

TipRanks 3h
Amgen, AstraZeneca announce FDA approval of Tezspire

Amgen (AMGN) and AstraZeneca (AZN) announced that the U.S. FDA approved Tezspire for the add-on maintenance treatment of inadequately controlled chronic rhinosi...

TipRanks 7h
AstraZeneca’s Saphnelo recommended for approval in EU

AstraZeneca (AZN) said that Saphnelo has been recommended for approval in the European Union as a self-administered once-weekly pre-filled pen for adult patient...

Nasdaq 7h
AstraZeneca's Imfinzi Improves Disease-Free Survival In Early-Stage Bladder Cancer

(RTTNews) - AstraZeneca (AZN), Friday announced positive Phase III results from its POTOMAC trial, showing that adding one year of treatment with Imfinzi; durva...

AstraZeneca's Imfinzi Improves Disease-Free Survival In Early-Stage Bladder Cancer

Analyst ratings

77%

of 31 ratings
Buy
77.4%
Hold
19.4%
Sell
3.2%

More AZN News

TipRanks 11h
AstraZeneca announces results from POTOMAC Phase III trial

Positive results from the POTOMAC Phase III trial showed adding one year of treatment with AstraZeneca’s (AZN) IMFINZI to BCG induction and maintenance therapy...

TipRanks 11h
AstraZeneca announces IMFINZI improvement in secondary endpoint of OS

Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) IMFINZI in combination with standard-of-care FLOT c...

TipRanks 1d
AstraZeneca’s New Study on AZD0516: A Potential Game-Changer for Metastatic Prostate Cancer

AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unloc...

TipRanks 1d
HER-TEMPO Study: Real-World Insights on Trastuzumab Deruxtecan

AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unloc...

Bloomberg 1d
AstraZeneca Gets Rare Sell as Deutsche Bank Has Pipeline Worries

AstraZeneca Plc got a rare sell rating on Thursday as Deutsche Bank AG analysts downgraded the British drugmaker, taking a more skeptical view on the company’s...

AstraZeneca Gets Rare Sell as Deutsche Bank Has Pipeline Worries
TipRanks 2d
AstraZeneca downgraded to Sell from Hold at Deutsche Bank

Deutsche Bank downgraded AstraZeneca (AZN) to Sell from Hold with a price target of 10,500 GBp, down from 11,000 GBp. The shares are trading at the top of their...

TipRanks 2d
AstraZeneca unveils manufacturing facility in Texas

AstraZeneca (AZN) announces the unveiling of its newly-expanded, state-of-the-art manufacturing facility in Coppell, Texas. The expansion project will double th...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.